Investor Presentaiton
Pfizer's Differentiated Immuno-Inflammatory Pipeline and Portfolio Brings
Potential Value to Patients and Shareholders
•
•
.
Serving Patients
Pfizer is committed to the patients
we serve
Heterogeneity of I&I conditions
mean that patients need options to
find relief
Diverse offering of medicines best
serves those suffering from
immuno-inflammatory diseases
•
•
Strong Strategic Fit
Pfizer capabilities aligned to Etrasimod
potential therapy areas
S1P MOA provides diversification to our
pipeline with broad applicability in
multiple indications of interest
Potential early entry into UC aligns with
current Pfizer commercial expertise and a
potential AD launch enhances medical
dermatology presence
Pfizer
Inflammation & Immunology
•
•
Value to Shareholders
Proposed acquisition aligns with our
broader capital allocation strategy to
establish a portfolio of both late and
early-stage to support 2025-2030 topline
growth
Deal provides value to both Pfizer and
Arena shareholders; Pfizer can effectively
commercialize Etrasimod with global
expertise
14View entire presentation